Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the IDH1 Inhibitor, IDH305, for the Treatment of IDH1 Mutated Low Grade Glioma Patients Who Have Measurable 2HG by MR Spectroscopy

NCT02987010 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT02987010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02987010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the IDH1 Inhibitor, IDH305, for the Treatment of IDH1 Mutated Low Grade Glioma Patients Who Have Measurable 2HG by MR Spectroscopy
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2017
Completion date
January 31, 2019
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioma